pharmacogenomics testing
Pronunciation: far-mah-ko-jee-NOM-iks
Genetic testing to predict individual responses to psychiatric medications based on genetic variations.
Full Definition
Pharmacogenomics testing involves analyzing specific genetic variations that affect how individuals metabolize and respond to psychiatric medications. These tests examine genes encoding drug-metabolizing enzymes (such as CYP2D6, CYP2C19), drug transporters, and drug targets to predict medication efficacy and adverse reaction risk. In psychiatry, this testing is increasingly used to guide antidepressant, antipsychotic, and mood stabilizer selection, potentially reducing trial-and-error prescribing and improving treatment outcomes. Results are typically categorized as poor, intermediate, normal, or ultrarapid metabolizers for specific drug classes. While promising, the clinical utility continues to evolve, and results should be integrated with clinical judgment, patient history, and other relevant factors rather than used as sole prescribing determinants.
Usage
Usage note: May be abbreviated as PGx; distinguish from general genetic testing for disease susceptibility.
In Context
- "Pharmacogenomics testing revealed the patient was a poor metabolizer of CYP2D6 substrates, explaining previous medication failures." — medication review
- "The clinic implemented pharmacogenomics testing protocols for treatment-resistant depression cases." — quality improvement